- Wainberg, Z. A., Shitara, K., Van Cutsem, E., Wyrwicz, L., Lee, K. W., Kudaba, I., . . . Tabernero, J. (2022). Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. Journal of Clinical Oncology, 40(4), 243. https://doi.org/10.1200/JCO.2022.40.4_suppl.243 (Meeting abstract)
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
on 16 de maig de 2022
with No hi ha comentaris
Deixa un comentari